Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.49 |
| ▸ | SCN1A | P35498 | 3/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10442252 | 0.87 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL19332958 | 0.87 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL19325672 | 0.87 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL21911297 | 0.85 | SLC6A3 (0.43) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL19002737 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL17069296 | 0.79 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL3103040 | 0.79 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL17069299 | 0.79 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL3827027 | 0.78 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| Ammonia Solution, Strong SCHEMBL6267830 | 0.78 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-11-08 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
| US-8927710-B2 | Substituted polycyclic carbamoylpyridone derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | LUC7L2, CXCR6, RRP12 | SLC6A2 3627/4885SLC6A4 4194/4885SLC6A3 3620/4885 |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER4 | SLC6A2 1699/4885SLC6A4 662/4885SLC6A3 1603/4885 |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | FABP1, POLRMT, SREBF1 | SLC6A2 2737/4885SLC6A4 2694/4885SLC6A3 3560/4885 |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | SLC6A2 4809/4885SLC6A4 3493/4885SLC6A3 4564/4885 |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | SLC6A2 4742/4885SLC6A4 4710/4885SLC6A3 4709/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | SLC6A2 4742/4885SLC6A4 4710/4885SLC6A3 4709/4885 |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR39, GPR65 | SLC6A2 2752/4885SLC6A4 2436/4885SLC6A3 3245/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | SLC6A2 4809/4885SLC6A4 3493/4885SLC6A3 4564/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | SLC6A2 3193/4885SLC6A4 3868/4885SLC6A3 4569/4885 |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | SLC6A2 325/4885SLC6A4 99/4885SLC6A3 495/4885 |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | SLC6A2 3881/4885SLC6A4 3340/4885SLC6A3 3291/4885 |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | SLC6A2 4424/4885SLC6A4 2491/4885SLC6A3 4230/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SLC6A2 4853/4885SLC6A4 4876/4885SLC6A3 4779/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | SLC6A2 4853/4885SLC6A4 4876/4885SLC6A3 4779/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SLC6A2 4853/4885SLC6A4 4876/4885SLC6A3 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.